- Home
- XPER vs ERAS Comparison
XPER vs ERAS Comparison
Compare XPER & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- ERAS
- Stock Information
- Founded
- XPER 1990
- ERAS 2018
- Country
- XPER United States
- ERAS United States
- Employees
- XPER N/A
- ERAS N/A
- Industry
- XPER Semiconductors
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- XPER Technology
- ERAS Health Care
- Exchange
- XPER Nasdaq
- ERAS Nasdaq
- Market Cap
- XPER 463.5M
- ERAS 396.6M
- IPO Year
- XPER 2003
- ERAS 2021
- Fundamental
- Price
- XPER $8.01
- ERAS $1.39
- Analyst Decision
- XPER Strong Buy
- ERAS Strong Buy
- Analyst Count
- XPER 3
- ERAS 6
- Target Price
- XPER $19.00
- ERAS $4.83
- AVG Volume (30 Days)
- XPER 337.1K
- ERAS 1.5M
- Earning Date
- XPER 05-07-2025
- ERAS 05-20-2025
- Dividend Yield
- XPER N/A
- ERAS N/A
- EPS Growth
- XPER N/A
- ERAS N/A
- EPS
- XPER N/A
- ERAS N/A
- Revenue
- XPER $488,877,000.00
- ERAS N/A
- Revenue This Year
- XPER $0.74
- ERAS N/A
- Revenue Next Year
- XPER $8.45
- ERAS N/A
- P/E Ratio
- XPER N/A
- ERAS N/A
- Revenue Growth
- XPER N/A
- ERAS N/A
- 52 Week Low
- XPER $6.29
- ERAS $1.01
- 52 Week High
- XPER $11.08
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- XPER 65.13
- ERAS 51.46
- Support Level
- XPER $6.36
- ERAS $1.37
- Resistance Level
- XPER $7.46
- ERAS $1.61
- Average True Range (ATR)
- XPER 0.26
- ERAS 0.15
- MACD
- XPER 0.10
- ERAS 0.00
- Stochastic Oscillator
- XPER 92.70
- ERAS 54.17
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.